A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

NCT01499368 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

495

Enrollment

INDUSTRY

Sponsor class

Conditions

Erosive Esophagitis

Interventions

DRUG: Lafutidine
DRUG: Famotidine
DRUG: Omeprazole

Sponsor

Boryung Pharmaceutical Co., Ltd